NS
Article DetailSEC EDGAR Filings
SEC EDGAR Filings
8-K - Spyre Therapeutics, Inc. - 7.01 / 8.01 / 9.01
Filed:
2026-04-13
AccNo:
0001628280-26-024831
Size:
4 MB
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits
发布时间04/13 11:46 UTC
首次发现04/13 11:47 UTC
热度105.4
重要度64
情绪0.00
站内整理正文
优先显示结构化正文；如果正文还未抽出，则回退到摘要。
sec_edgar_index_v1 · 675 字符
Form 8-K - Current report: SEC Accession No. 0001628280-26-024831
Filing Date: 2026-04-13
Accepted: 2026-04-13 07:46:49
Documents: 45
Period of Report: 2026-04-13
Items: Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Spyre Therapeutics, Inc. (Filer) CIK : 0001636282 (see all company filings) EIN. : 464312787 | State of Incorp.: DE | Fiscal Year End: 1231 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)
1 | 8-K | syre-20260413.htm iXBRL | 8-K
2 | EX-99.1 | exhibit991-8xkdatarelease.htm | EX-99.1
3 | EX-99.2 | exhibit992set2.htm | EX-99.2
7 | exhibit992set2001.jpg | GRAPHIC | 108419